Atellica IM Total PSA II (tPSAII)
Siemens Healthcare Diagnostics, Inc. · Decision date Dec 3, 2025
What did the FDA approve?
FDA records P240021 as an original PMA application. The recorded decision is approval, dated Dec 3, 2025.
FDA approval order statement
Approval for the Atellica IM total PSA II (tPSAII):The Atellica IM total PSA II (tPSAII) assay is for in vitro diagnostic use in the quantitative measurement of total prostate-specific antigen (PSA) in human serum and plasma (EDTA and lithium-heparin) using the Atellica IM Analyzer. This assay is indicated as an aid in the detection of prostate cancer in conjunction with a digital rectal exam (DRE) in men aged 50 years and older. A prostate biopsy is required for the diagnosis of prostate cancer.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Immunology
- Decision date
- Dec 3, 2025
Regulatory record facts
- Identifier
- P240021
- Regulatory pathway
- Premarket approval application
- Applicant
- Siemens Healthcare Diagnostics, Inc.
- Product code
- MTF
- Decision code
- APPR
- Decision date
- Dec 3, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Total, prostate specific antigen (noncomplexed & complexed) for detection of prostate cancer.
- Applicant
- Siemens Healthcare Diagnostics, Inc.
- Product code
- MTF
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P240021 received
Application receipt date recorded by FDA.
P240021 · FDA decision
APPR
P240021/S001 · Related supplement
Atellica IM Total PSA II (tPSAII)
Timeline entries are records held by MedtechLedger for P240021. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240021
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Atellica IM Total PSA II (tPSAII)P240021/S001 | Siemens Healthcare Diagnostics, Inc. | PMA supplement | Aug 26, 2026 | FDA |
Explore the linked device profile
Other records with product code MTF
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
IMMULITE Systems PSAP930027/S041 | Siemens Healthcare Diagnostics, Inc. | PMA supplement | Sep 22, 2026 | FDA |
IMMULITE Systems PSAP930027/S040 | Siemens Healthcare Diagnostics, Inc. | PMA supplement | Aug 20, 2026 | FDA |
IMMULITE 2000 PSAP930027/S039 | Siemens Healthcare Diagnostics, Inc. | PMA supplement | Jul 27, 2026 | FDA |
| Roche Diagnostics Corp. | PMA supplement | Apr 29, 2026 | FDA | |
IMMULITE 2000 PSAP930027/S038 | Siemens Healthcare Diagnostics, Inc. | PMA supplement | Apr 21, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Siemens Healthcare Diagnostics, Inc.
- Headquarters
- Not reported
- Brand website
- siemens-healthineers.com
- FDA applicant address
- 511 Benedict Ave., Tarrytown, NY, 10591
Sources and methodology
- Original FDA record: P240021
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



